The head of the Interagency Autism Coordinating Committee, which oversees roughly $2 billion in autism research funding, has been replaced with John Gaitanis, a pediatric neurologist recently appointed to the National Institutes of Health’s child health institute. Gaitanis co-founded Meadow Biosciences, a telehealth startup focused on helping autistic children access leucovorin, a pharmaceutical intervention.
The appointment has drawn attention because leucovorin gained prominence after President Trump publicly promoted the treatment during a news conference, despite limited clinical evidence supporting its effectiveness in improving speech outcomes. Gaitanis’s leadership role gives him significant influence over how federal research dollars are allocated within the autism research space.
Previous chair Sylvia Fogel will retain her position on the autism council. During her tenure, Fogel advocated for increased autism research funding and oversaw the development of a strategic plan that shifted focus away from genetic research toward investigations of environmental factors. She also engaged in contentious discussions with other committee members regarding research priorities and direction.
The transition reflects broader questions about how financial interests and research priorities intersect within federal health agencies, particularly when committee leadership has commercial stakes in treatments under their purview. The appointment occurs amid ongoing debates about research funding, scientific independence, and the role of political appointees in determining which health research receives federal support.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI